Introduction
vitiligo, Vogt-Koyanagi-Harada, poliosis, autoimmune disorder, uveitis, VKH disease, alopecia, VKH
VITILIGO, POLIOSIS, AUTOIMMUNE DISORDER, DISEASE, UVEITIS, ADVERSE EFFECTS, REMISSION, ALOPECIA
Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disorder manifested as bilateral uveitis with or without vitiligo, poliosis, alopecia, meningeal manifestations, and auditory-vestibular dysfunctionAlthough several drugs are used for VKH disease in clinical practice, the therapeutic strategy for the disease is generally empirical. Systemic corticosteroids remain the mainstay of treatment for VKH disease, but they frequently cause adverse effects or intolerance which have tempered the overall effectivenessIn this work, we conducted a pragmatic, blinded-end point, non-inferiority, randomized trial to compare clinical effectiveness and safety profile between cyclosporine-based conventional immunosuppressant strategy and adalimumab-based biologic strategy in combination with corticosteroids for the 26-week induction of remission in VKH disease.